Advertisement

SJS/TEN 2019: From science to translation

      Abstract

      Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are potentially life-threatening, immune-mediated adverse reactions characterized by widespread erythema, epidermal necrosis, and detachment of skin and mucosa. Efforts to grow and develop functional international collaborations and a multidisciplinary interactive network focusing on SJS/TEN as an uncommon but high burden disease will be necessary to improve efforts in prevention, early diagnosis and improved acute and long-term management. SJS/TEN 2019: From Science to Translation was a 1.5-day scientific program held April 26–27, 2019, in Vancouver, Canada. The meeting successfully engaged clinicians, researchers, and patients and conducted many productive discussions on research and patient care needs.

      Abbreviations:

      ADR (Adverse drug reaction), AIDS (Acquired immunodeficiency syndrome), ALDEN (Algorithm of drug causality for epidermal necrolysis), ALK (Anaplastic lymphoma kinase), AUS-SCAR (Australian registry of severe cutaneous adverse reactions), CBZ (Carbamazepine), CFH (Complement factor H), CLET (Cultivated limbal epithelial sell transplantation), COMET (Cultivated oral mucosal epithelial transplantation), CPNDS (Canadian Pharmacogenomics Network for Drug Safety), DILI (Drug-induced liver injury), DRESS (Drug reaction with eosinophilia and systemic symptoms), EHR (Electronic health records), EMA (European Medicines Agency), EpiPGx (Epilepsy Pharmacogenomics), eRMR (Electronic Reaction Monitoring Report), FDA (Food and Drug Administration), GWAS (Genome-wide association study), HIV (Human immunodeficiency virus), HLA (Human leukocyte antigen), IVIg (Intravenous immune globulin), iSCAR (International Congress on Cutaneous Adverse Drug Reaction), ITCH (International Consortium on Drug Hypersensitivity), LSCD (Limbal stem cell deficiency), MPE (Maculopapular eruption), NATIENS (North American Therapeutics in Epidermal Necrolysis Syndrome Network), PGx (Pharmacogenomics), PMDA (Pharmaceuticals and Medical Devices Agency (in Japan)), PRAC (Pharmacovigilance Risk Assessment Committee), QOL (Quality of life), RegiSCAR (Multinational registry of Severe Cutaneous Adverse Reactions to drugs and collection of biological samples), SCAR (Severe cutaneous adverse reaction), SDH (Society of Dermatology Hospitalists), SEAPharm (Southeast Asian Pharmacogenomic Network), SOMET (Simple oral mucosal epithelial transplantation), SJS (Stevens-Johnson syndrome), TB (Tuberculosis), TCR (T cell receptor), TEN (Toxic epidermal necrolysis), TFDA (Taiwan Food and Drug Administration), T-SCAR (Taiwan Severe Cutaneous Adverse Reaction Consortium)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Dermatological Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • White K.D.
        • Abe R.
        • Ardern-Jones M.
        • Beachkofsky T.
        • Bouchard C.
        • Carleton B.
        • Chodosh J.
        • Cibotti R.
        • Davis R.
        • Denny J.C.
        • Dodiuk-Gad R.P.
        • Ergen E.N.
        • Goldman J.L.
        • Holmes J.H.
        • Hung S.I.
        • Lacouture M.E.
        • Lehloenya R.J.
        • Mallal S.
        • Manolio T.A.
        • Micheletti R.G.
        • Mitchell C.M.
        • Mockenhaupt M.
        • Ostrov D.A.
        • Pavlos R.
        • Pirmohamed M.
        • Pope E.
        • Redwood A.
        • Rosenbach M.
        • Rosenblum M.D.
        • Roujeau J.C.
        • Saavedra A.P.
        • Saeed H.N.
        • Struewing J.P.
        • Sueki H.
        • Sukasem C.
        • Sung C.
        • Trubiano J.A.
        • Weintraub J.
        • Wheatley L.M.
        • Williams K.B.
        • Worley B.
        • Chung W.H.
        • Shear N.H.
        • Phillips E.J.
        SJS/TEN 2017: building multidisciplinary networks to drive science and translation.
        J. Allergy Clin. Immunol. Pract. 2018; 6: 38-69
        • Mallal S.
        • Phillips E.
        • Carosi G.
        • Molina J.M.
        • Workman C.
        • Tomazic J.
        • Jägel-Guedes E.
        • Rugina S.
        • Kozyrev O.
        • Cid J.F.
        • Hay P.
        • Nolan D.
        • Hughes S.
        • Hughes A.
        • Ryan S.
        • Fitch N.
        • Thorborn D.
        • Benbow A.
        • PREDICT-1 Study Team
        HLA-B*5701 screening for hypersensitivity to abacavir.
        N. Engl. J. Med. 2008; 358: 568-579
        • Chen P.
        • Lin J.J.
        • Lu C.S.
        • Ong C.T.
        • Hsieh P.F.
        • Yang C.C.
        • Tai C.T.
        • Wu S.L.
        • Lu C.H.
        • Hsu Y.C.
        • Yu H.Y.
        • Ro L.S.
        • Lu C.T.
        • Chu C.C.
        • Tsai J.J.
        • Su Y.H.
        • Lan S.H.
        • Sung S.F.
        • Lin S.Y.
        • Chuang H.P.
        • Huang L.C.
        • Chen Y.J.
        • Tsai P.J.
        • Liao H.T.
        • Lin Y.H.
        • Chen C.H.
        • Chung W.H.
        • Hung S.I.
        • Wu J.Y.
        • Chang C.F.
        • Chen L.
        • Chen Y.T.
        • Shen C.Y.
        • Taiwan SJS Consortium
        Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.
        N. Engl. J. Med. 2011; 364: 1126-1133
        • Zhang F.R.
        • Liu H.
        • Irwanto A.
        • Fu X.A.
        • Li Y.
        • Yu G.Q.
        • Yu Y.X.
        • Chen M.F.
        • Low H.Q.
        • Li J.H.
        • Bao F.F.
        • Foo J.N.
        • Bei J.X.
        • Jia X.M.
        • Liu J.
        • Liany H.
        • Wang N.
        • Niu G.Y.
        • Wang Z.Z.
        • Shi B.Q.
        • Tian H.Q.
        • Liu H.X.
        • Ma S.S.
        • Zhou Y.
        • You J.B.
        • Yang Q.
        • Wang C.
        • Chu T.S.
        • Liu D.C.
        • Yu X.L.
        • Sun Y.H.
        • Ning Y.
        • Wei Z.H.
        • Chen S.L.
        • Chen X.C.
        • Zhang Z.X.
        • Liu Y.X.
        • Pulit S.L.
        • Wu W.B.
        • Zheng Z.Y.
        • Yang R.D.
        • Long H.
        • Liu Z.S.
        • Wang J.Q.
        • Li M.
        • Zhang L.H.
        • Wang H.
        • Wang L.M.
        • Xiao P.
        • Li J.L.
        • Huang Z.M.
        • Huang J.X.
        • Li Z.
        • Liu J.
        • Xiong L.
        • Yang J.
        • Wang X.D.
        • Yu D.B.
        • Lu X.M.
        • Zhou G.Z.
        • Yan L.B.
        • Shen J.P.
        • Zhang G.C.
        • Zeng Y.X.
        • de Bakker P.I.W.
        • Chen S.M.
        • Liu J.J.
        HLA-B*13:01 and the dapsone hypersensitivity syndrome.
        N. Engl. J. Med. 2013; 369: 1620-1628
        • Ko T.M.
        • Tsai C.Y.
        • Chen S.Y.
        • Chen K.S.
        • Yu K.H.
        • Chu C.S.
        • Huang C.M.
        • Wang C.R.
        • Weng C.T.
        • Yu C.L.
        • Hsieh S.C.
        • Tsai J.C.
        • Lai W.T.
        • Tsai W.C.
        • Yin G.D.
        • Ou T.T.
        • Cheng K.H.
        • Yen J.H.
        • Liou T.L.
        • Lin T.H.
        • Chen D.Y.
        • Hsiao P.J.
        • Weng M.Y.
        • Chen Y.M.
        • Chen C.H.
        • Liu M.F.
        • Yen H.W.
        • Lee J.J.
        • Kuo M.C.
        • Wu C.C.
        • Hung S.Y.
        • Luo S.F.
        • Yang Y.H.
        • Chuang H.P.
        • Chou Y.C.
        • Liao H.T.
        • Wang C.W.
        • Huang C.L.
        • Chang C.S.
        • Lee M.T.M.
        • Chen P.
        • Wong C.S.
        • Chen C.H.
        • Wu J.Y.
        • Chen Y.T.
        • Shen C.Y.
        • Taiwan Allopurinol-SCAR Consortium
        Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
        BMJ. 2015; 351: h4848
        • Manolio T.A.
        • Hutter C.M.
        • Avigan M.
        • Cibotti R.
        • Davis R.L.
        • Denny J.C.
        • La Grenade L.
        • Wheatley L.M.
        • Carrington M.N.
        • Chantratita W.
        • Chung W.H.
        • Dalton A.D.
        • Hung S.I.
        • Lee M.T.M.
        • Leeder J.S.
        • Lertora J.J.L.
        • Mahasirimongkol S.
        • McLeod H.L.
        • Mockenhaupt M.
        • Pacanowski M.
        • Phillips E.J.
        • Pinheiro S.
        • Pirmohamed M.
        • Sung C.
        • Suwankesawong W.
        • Trepanier L.
        • Tumminia S.J.
        • Veenstra D.
        • Yuliwulandari R.
        • Shear N.H.
        Research directions in genetic predispositions to Stevens-Johnson syndrome/toxic epidermal necrolysis.
        Clin. Pharmacol. Ther. 2018; 103: 390-394
        • Le H.G.
        • Saeed H.
        • Mantagos I.S.
        • Mitchell C.M.
        • Goverman J.
        • Chodosh J.
        Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: a survey.
        Burns. 2016; 42: 830-835
        • Lim V.M.
        • Do A.
        • Berger T.G.
        • Nguyen A.H.
        • DeWeese J.
        • Malone J.D.
        • Jordan K.
        • Hom F.
        • Tuffanelli L.
        • Fillari P.
        • Siu S.
        • Grossman R.
        A decade of burn unit experience with Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical pathological diagnosis and risk factor awareness.
        Burns. 2016; 42: 836-843
        • Garcia-Doval I.
        • LeCleach L.
        • Bocquet H.
        • Otero X.L.
        • Roujeau J.C.
        Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?.
        Arch. Dermatol. 2000; 136: 323-327
        • González-Herrada C.
        • Rodríguez-Martín S.
        • Cachafeiro L.
        • Lerma V.
        • González O.
        • Lorente J.A.
        • Rodríguez-Miguel A.
        • González-Ramos J.
        • Roustan G.
        • Ramírez E.
        • Bellón T.
        • de Abajo F.J.
        • Bellón T.
        • Cabañas R.
        • Cachafeiro L.
        • García de Lorenzo A.
        • González-Ramos J.
        • Hernández O.
        • Herranz P.
        • Ramírez E.
        • Bravo E.R.
        • Alonso Y.
        • Aramburu J.A.
        • Cámara N.
        • González O.
        • González-Herrada C.
        • Laosa O.
        • Lorente J.A.
        • Moscoso A.
        • Payares C.
        • Roustan G.
        • de Abajo F.J.
        • Quesada A.
        • Lerma V.
        • Rodríguez-Martín S.
        Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches.
        J. Invest. Dermatol. 2017; 137: 2092-2100
        • Wang C.W.
        • Yang L.Y.
        • Chen C.B.
        • Ho H.C.
        • Hung S.I.
        • Yang C.H.C.Y.
        • Chang C.J.
        • Su S.C.
        • Hui R.C.Y.
        • Chin S.W.
        • Huang L.F.
        • Lin Y.Y.W.
        • Chang W.Y.
        • Fan W.L.
        • Yang C.H.C.Y.
        • Ho J.C.
        • Chang Y.C.
        • Lu C.W.
        • Chung W.H.
        • the Taiwan Severe Cutaneous Adverse Reaction (TSCAR) consortium
        Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
        J. Clin. Invest. 2018; 128: 985-996
        • McPherson T.
        • Exton L.S.
        • Biswas S.
        • Creamer D.
        • Dziewulski P.
        • Newell L.
        • Tabor K.L.
        • Wali G.N.
        • Walker G.
        • Walker R.
        • Walker S.
        • Young A.E.
        • Mohd Mustapa M.F.
        • Murphy R.
        British Association of Dermatologists’ guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018.
        Br. J. Dermatol. 2019; 181: 37-54
        • Schwartz R.A.
        • McDonough P.H.
        • Lee B.W.
        Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.
        J. Am. Acad. Dermatol. 2013; 69 (e1–16): 187
        • Meneux E.
        • Wolkenstein P.
        • Haddad B.
        • Roujeau J.C.
        • Revuz J.
        • Paniel B.J.
        Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases.
        Obstet. Gynecol. 1998; 91: 283-287
        • Niemeijer I.C.
        • van Praag M.C.G.
        • van Gemund N.
        Relevance and consequences of erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in gynecology.
        Arch. Gynecol. Obstet. 2009; 280: 851-854
        • Gregory D.G.
        New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome.
        Ophthalmology. 2016; 123: 1653-1658
        • Kohanim S.
        • Palioura S.
        • Saeed H.N.
        • Akpek E.K.
        • Amescua G.
        • Basu S.
        • Blomquist P.H.
        • Bouchard C.S.
        • Dart J.K.
        • Gai X.
        • Gomes J.A.P.
        • Gregory D.G.
        • Iyer G.
        • Jacobs D.S.
        • Johnson A.J.
        • Kinoshita S.
        • Mantagos I.S.
        • Mehta J.S.
        • Perez V.L.
        • Pflugfelder S.C.
        • Sangwan V.S.
        • Sippel K.C.
        • Sotozono C.
        • Srinivasan B.
        • Tan D.T.H.
        • Tandon R.
        • Tseng S.C.G.
        • Ueta M.
        • Chodosh J.
        Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis -- a comprehensive review and guide to therapy. II. Ophthalmic disease.
        Ocul. Surf. 2016; 14: 168-188
        • Sharma N.
        • Thenarasun S.A.
        • Kaur M.
        • Pushker N.
        • Khanna N.
        • Agarwal T.
        • Vajpayee R.B.
        Adjuvant role of amniotic membrane transplantation in acute ocular Stevens–Johnson syndrome.
        Ophthalmology. 2016; 123: 484-491
        • Shanbhag S.S.
        • Rashad R.
        • Chodosh J.
        • Saeed H.N.
        Long-term impact of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome/toxic epidermal necrolysis.
        Am. J. Ophthalmol. 2019; 208: 331-341
        • Ueta M.
        • Kannabiran C.
        • Wakamatsu T.H.
        • Kim M.K.
        • Yoon K.C.
        • Seo K.Y.
        • Joo C.K.
        • Sangwan V.
        • Rathi V.
        • Basu S.
        • Shamaila A.
        • Lee H.S.
        • Yoon S.
        • Sotozono C.
        • Gomes J.Á.P.
        • Tokunaga K.
        • Kinoshita S.
        Trans-ethnic study confirmed independent associations of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications.
        Sci. Rep. 2014; 4: 5981
        • Roujeau J.C.
        • Dunant A.
        • Mockenhaupt M.
        Epidermal necrolysis, ocular complications, and “Cold Medicines”.
        J. Allergy Clin. Immunol. Pract. 2018; 6: 703-704
        • Ueta M.
        Results of detailed investigations into Stevens-Johnson syndrome with severe ocular complications.
        Invest. Ophthalmol. Vis. Sci. 2018; 59: DES183-DES191
        • Blumenthal K.G.
        • Wickner P.G.
        • Lau J.J.
        • Zhou L.
        Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system.
        J. Allergy Clin. Immunol. Pract. 2015; 3 (e1): 277-280
        • Wong A.
        • Seger D.L.
        • Lai K.H.
        • Goss F.R.
        • Blumenthal K.G.
        • Zhou L.
        Drug hypersensitivity reactions documented in electronic health records within a large health system.
        J. Allergy Clin. Immunol. Pract. 2019; 7 (e3): 1253-1260
      1. European Medicines Agency (EMA)/Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on safety signals- List of safety signals discussed since September 2012, (2012). https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/signal-management/prac-recommendations-safety-signals#list-of-safety-signals-discussed-since-september-2012-section.

        • Tan-Koi W.C.
        • Sung C.
        • Chong Y.Y.
        • Lateef A.
        • Pang S.M.
        • Vasudevan A.
        • Aw D.
        • Lui N.L.
        • Lee S.X.
        • Ren E.C.
        • Koay E.S.
        • Tay Y.K.
        • Lim Y.L.
        • Lee H.Y.
        • Dong D.
        • Loke C.
        • Tan L.
        • Limenta M.
        • Lee E.J.
        • Toh D.
        • Chan C.L.
        Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.
        Pharmacogenomics. 2017; 18: 881-890
        • Sassolas B.
        • Haddad C.
        • Mockenhaupt M.
        • Dunant A.
        • Liss Y.
        • Bork K.
        • Haustein U.F.
        • Vieluf D.
        • Roujeau J.C.
        • Le Louet H.
        ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.
        Clin. Pharmacol. Ther. 2010; 88: 60-68
        • Amstutz U.
        • Shear N.H.
        • Rieder M.J.
        • Hwang S.
        • Fung V.
        • Nakamura H.
        • Connolly M.B.
        • Ito S.
        • Carleton B.C.
        • CPNDS Clinical Recommendation Group
        Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
        Epilepsia. 2014; 55: 496-506
        • Chung W.H.
        • Chang W.C.
        • Lee Y.S.
        • Wu Y.R.Y.Y.
        • Yang C.H.
        • Ho H.C.
        • Chen M.J.
        • Lin J.Y.
        • Hui R.C.Y.
        • Ho J.C.
        • Wu W.M.
        • Chen T.J.
        • Wu T.T.L.
        • Wu Y.R.Y.Y.
        • Hsih M.S.
        • Tu P.H.
        • Chang C.J.C.N.
        • Hsu C.K.C.N.
        • Wu T.T.L.
        • Choon S.E.
        • Hsu C.K.C.N.
        • Chen D.Y.
        • Liu C.S.
        • Lin C.Y.
        • Kaniwa N.
        • Saito Y.
        • Takahashi Y.
        • Nakamura R.
        • Azukizawa H.
        • Shi Y.
        • Wang T.H.
        • Chuang S.S.
        • Tsai S.F.
        • Chang C.J.C.N.
        • Chang Y.S.
        • Hung S.I.
        • Taiwan Severe Cutaneous Adverse Reaction Consortium, Japan Pharmacogenomics Data Science Consortium
        Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
        JAMA. 2014; 312: 525-534
        • Chen C.B.
        • Hsiao Y.H.
        • Wu T.T.L.
        • Hsih M.S.
        • Tassaneeyakul W.
        • Jorns T.P.
        • Sukasem C.
        • Hsu C.K.C.N.
        • Su S.C.
        • Chang W.C.
        • Hui R.C.Y.
        • Chu C.Y.
        • Chen Y.J.
        • Wu C.Y.
        • Hsu C.K.C.N.
        • Chiu T.M.
        • Sun P.L.
        • Lee H.E.
        • Yang C.Y.
        • Kao P.H.
        • Yang C.H.
        • Ho H.C.
        • Lin J.Y.
        • Chang Y.C.
        • Chen M.J.
        • Lu C.W.
        • Ng C.Y.
        • Kuo K.L.
        • Lin C.Y.
        • Yang C.S.
        • Chen D.P.
        • Chang P.Y.
        • Wu T.T.L.
        • Lin Y.J.
        • Weng Y.C.
        • Kuo T.T.
        • Hung S.I.
        • Chung W.H.
        • Taiwan Severe Cutaneous Adverse Reaction Consortium
        Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians.
        Neurology. 2017; 88: 78-86
        • Konvinse K.C.
        • Trubiano J.A.
        • Pavlos R.
        • James I.
        • Shaffer C.M.
        • Bejan C.A.
        • Schutte R.J.
        • Ostrov D.A.
        • Pilkinton M.A.
        • Rosenbach M.
        • Zwerner J.P.
        • Williams K.B.
        • Bourke J.
        • Martinez P.
        • Rwandamuriye F.
        • Chopra A.
        • Watson M.
        • Redwood A.J.
        • White K.D.
        • Mallal S.A.
        • Phillips E.J.
        HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.
        J. Allergy Clin. Immunol. 2019; 144: 183-192
        • Nicoletti P.
        • Barrett S.
        • McEvoy L.
        • Daly A.K.
        • Aithal G.
        • Lucena M.I.
        • Andrade R.J.
        • Wadelius M.
        • Hallberg P.
        • Stephens C.
        • Bjornsson E.S.
        • Friedmann P.
        • Kainu K.
        • Laitinen T.
        • Marson A.
        • Molokhia M.
        • Phillips E.
        • Pichler W.
        • Romano A.
        • Shear N.
        • Sills G.
        • Tanno L.K.
        • Swale A.
        • Floratos A.
        • Shen Y.
        • Nelson M.R.
        • Watkins P.B.
        • Daly M.J.
        • Morris A.P.
        • Alfirevic A.
        • Pirmohamed M.
        Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions.
        Clin. Pharmacol. Ther. 2019; 106: 1028-1036
        • McCormack M.
        • Gui H.
        • Ingason A.
        • Speed D.
        • Wright G.E.B.
        • Zhang E.J.
        • Secolin R.
        • Yasuda C.
        • Kwok M.
        • Wolking S.
        • Becker F.
        • Rau S.
        • Avbersek A.
        • Heggeli K.
        • Leu C.
        • Depondt C.
        • Sills G.J.
        • Marson A.G.
        • Auce P.
        • Brodie M.J.
        • Francis B.
        • Johnson M.R.
        • Koeleman B.P.C.
        • Striano P.
        • Coppola A.
        • Zara F.
        • Kunz W.S.
        • Sander J.W.
        • Lerche H.
        • Klein K.M.
        • Weckhuysen S.
        • Krenn M.
        • Gudmundsson L.J.
        • Stefánsson K.
        • Krause R.
        • Shear N.
        • Ross C.J.D.
        • Delanty N.
        • Pirmohamed M.
        • Carleton B.C.
        • Cendes F.
        • Lopes-Cendes I.
        • Liao W.
        • O’Brien T.J.
        • Sisodiya S.M.
        • Cherny S.
        • Kwan P.
        • Baum L.
        • Cavalleri G.L.
        • Kwan P.
        • Baum L.
        • Cavalleri G.L.
        • International League Against Epilepsy Consortium on Complex Epilepsies
        Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.
        Neurology. 2018; 90: e332-e341
        • Chung W.H.
        • Hung S.I.
        • Yang J.Y.
        • Su S.C.
        • Huang S.P.
        • Wei C.Y.
        • Chin S.W.
        • Chiou C.C.
        • Chu S.C.
        • Ho H.C.
        • Yang C.H.
        • Lu C.F.
        • Wu J.Y.
        • Liao Y.D.
        • Chen Y.T.
        Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.
        Nat. Med. 2008; 14: 1343-1350
        • Su S.C.
        • Mockenhaupt M.
        • Wolkenstein P.
        • Dunant A.
        • Le Gouvello S.
        • Chen C.B.
        • Chosidow O.
        • Valeyrie-Allanore L.
        • Bellon T.
        • Sekula P.
        • Wang C.W.
        • Schumacher M.
        • Kardaun S.H.
        • Hung S.I.
        • Roujeau J.C.
        • Chung W.H.
        Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis.
        J. Invest. Dermatol. 2017; 137: 1065-1073
        • Paulmann M.
        • Mockenhaupt M.
        Fever in Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric cases: laboratory work-up and antibiotic therapy.
        Pediatr. Infect. Dis. J. 2017; 36: 513-515
        • Peter J.
        • Choshi P.
        • Lehloenya R.J.
        Drug hypersensitivity in HIV infection.
        Curr. Opin. Allergy Clin. Immunol. 2019; 19: 272-282
        • Sekula P.
        • Dunant A.
        • Mockenhaupt M.
        • Naldi L.
        • Bouwes Bavinck J.N.
        • Halevy S.
        • Kardaun S.
        • Sidoroff A.
        • Liss Y.
        • Schumacher M.
        • Roujeau J.C.
        • RegiSCAR Study Group
        Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis.
        J. Invest. Dermatol. 2013; 133: 1197-1204
        • Lehloenya R.J.
        • Haitembu N.
        • Basera W.
        • Peter J.
        Lower-than-predicted mortality in a predominantly HIV-infected population with epidermal necrolysis regardless of HIV status: implications and challenges for interventional studies.
        J. Allergy Clin. Immunol. Pract. 2019; 7: 1653-1655
        • Dodiuk-Gad R.P.
        • Olteanu C.
        • Feinstein A.
        • Hashimoto R.
        • Alhusayen R.
        • Whyte-Croasdaile S.
        • Finkelstein Y.
        • Burnett M.
        • Sade S.
        • Cartotto R.
        • Jeschke M.
        • Shear N.H.
        Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis.
        Br. J. Dermatol. 2016; 175: 422-424
        • Hefez L.
        • Zaghbib K.
        • Sbidian E.
        • Valeyrie-Allanore L.
        • Allain M.
        • Duong T.A.
        • Colin A.
        • Bellivier F.
        • Romano H.
        • de Prost N.
        • Chazelas K.
        • Chosidow O.
        • Wolkenstein P.
        • Ingen-Housz-Oro S.
        Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients.
        Br. J. Dermatol. 2019; 180: 1206-1213
        • Olteanu C.
        • Shear N.H.
        • Chew H.F.
        • Hashimoto R.
        • Alhusayen R.
        • Whyte-Croasdaile S.
        • Finkelstein Y.
        • Burnett M.
        • Ziv M.
        • Sade S.
        • Jeschke M.G.
        • Dodiuk-Gad R.P.
        Severe physical complications among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis.
        Drug Saf. 2018; 41: 277-284
        • Sheridan R.L.
        • Schulz J.T.
        • Ryan C.M.
        • Schnitzer J.J.
        • Lawlor D.
        • Driscoll D.N.
        • Donelan M.B.
        • Tompkins R.G.
        Long-term consequences of toxic epidermal necrolysis in children.
        Pediatrics. 2002; 109: 74-78
        • Paquet P.
        • Jacob E.
        • Quatresooz P.
        • Jacquemin D.
        • Piérard G.E.
        Delayed reepithelialization and scarring deregulation following drug-induced toxic epidermal necrolysis.
        Burns. 2007; 33: 100-104
        • Kreft B.
        • Lieser U.
        • Haase R.
        • Marsch W.C.
        • Wohlrab J.
        Extensive hypertrophic scarring after toxic epidermal necrolysis in a child.
        Pediatr. Dermatol. 2014; 31: 527-528
        • Anderson R.R.
        • Donelan M.B.
        • Hivnor C.
        • Greeson E.
        • Ross E.V.
        • Shumaker P.R.
        • Uebelhoer N.S.
        • Waibel J.S.
        Laser treatment of traumatic scars with an emphasis on ablative fractional laser resurfacing: consensus report.
        JAMA Dermatol. 2014; 150: 187-193
        • Miletta N.R.
        • Donelan M.B.
        • Hivnor C.M.
        Management of trauma and burn scars: the dermatologist’s role in expanding patient access to care.
        Cutis. 2017; 100: 18-20
        • Chung W.H.
        • Pan R.Y.
        • Chu M.T.
        • Chin S.W.
        • Huang Y.L.
        • Wang W.C.
        • Chang J.Y.
        • Hung S.I.
        Oxypurinol-specific T cells possess preferential TCR clonotypes and express granulysin in allopurinol-induced severe cutaneous adverse reactions.
        J. Invest. Dermatol. 2015; 135: 2237-2248
        • Pan R.Y.
        • Chu M.T.
        • Wang C.W.
        • Lee Y.S.
        • Lemonnier F.
        • Michels A.W.
        • Schutte R.
        • Ostrov D.A.
        • Chen C.B.
        • Phillips E.J.
        • Mallal S.A.
        • Mockenhaupt M.
        • Bellón T.
        • Tassaneeyakul W.
        • White K.D.
        • Roujeau J.C.
        • Chung W.H.
        • Hung S.I.
        Identification of drug-specific public TCR driving severe cutaneous adverse reactions.
        Nat. Commun. 2019; 10: 3569
        • Cardone M.
        • Garcia K.
        • Tilahun M.E.
        • Boyd L.F.
        • Gebreyohannes S.
        • Yano M.
        • Roderiquez G.
        • Akue A.D.
        • Juengst L.
        • Mattson E.
        • Ananthula S.
        • Natarajan K.
        • Puig M.
        • Margulies D.H.
        • Norcross M.A.
        A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity.
        J. Clin. Invest. 2018; 128: 2819-2832

      Biography

      Dr. Wan-Chun Chang is a Postdoctoral Fellow in the Department of Pediatrics, University of British Columbia and British Columbia Children’s Hospital Research Institute in Vancouver, Canada who along with Drs. Bruce Carleton, Elizabeth Phillips, Wen-Hung Chung, Agnieszka Biala, and Kristina Williams helped coordinate SJS/TEN 2019 conference. During her training, Dr. Chang has focused on the pharmacogenomics of drug-induced severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN). Her current research at the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) involves both pharmacogenomics and immunogenesis of the antiepileptic and antibiotic drug-induced SCAR in patients with different ancestries.

      Linked Article